On October 29, 2025, Bio-Rad Laboratories reported third-quarter earnings with sales of US$653 million and a net loss of US$341.9 million, while also completing a major share repurchase and announcing ...

Biodesix will perform the clinical validation of ddPLEX ESR1 Mutation Detection Assay for advanced breast cancer ...

Biodesix announces expanded Bio-Rad Laboratories partnership agreement to develop Droplet Digital PCR high complexity assays: Louisville, Colorado Friday, October 24, 2025, 12:00 ...

Digital PCR (dPCR) is an excellent tool for rare target analysis applications because, unlike traditional PCR methods, dPCR divides samples into thousands of individual microreactions, then amplifies ...

Biodesix has expanded its collaboration with Bio-Rad Laboratories for the development and clinical validation of in vitro diagnostic (IVD) assays, designed to facilitate the identification of a ...

Learn how a nutraceutical brand is investing in responsible and transparent manufacturing.

Biodesix, Inc. (NYSE: BDSX), a leading diagnostics solutions company, today announced the signing of an expanded partnership agreement under which Biodesix will ...

Scientists used DNA testing on 1,200-year-old feces to detect E. coli, pinworms, and Giardia in ancient Mexico, and found ...

Q3 2025 Management View Jonathan DiVincenzo, President & COO, reported that "revenue was consistent with our outlook and operating margin exceeded consensus, a testament to the discipline and agility ...

Explore India's pursuit of GI tags for artisans, addressing IP rights, market challenges, and the impact on traditional ...

Q3 2025 Revenue of $21.8 million, an increase of 20% over Q3 2024;Q3 2025 gross profit margin of 81%, a 400-basis point improvement from Q3 ...

A customer of a former Labour minister’s allegedly fraudulent Covid-19 testing firm told a court the company offered her a ...